Image

Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications

Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications

Not Recruiting
18-75 years
All
Phase N/A

Powered by AI

Overview

This retrospective study investigates the relationship between cardiopulmonary bypass (CPB) duration and the incidence of gastrointestinal complications (GICs) in patients undergoing heart valve replacement. Patients will be grouped into a normal CPB group (CPB <120 minutes) and a prolonged CPB group (CPB ≥120 minutes). The study aims to determine whether prolonged CPB time is associated with a higher risk of GICs and to evaluate the outcomes and recovery process for patients who develop GICs postoperatively.

Description

Heart valve replacement with CPB carries a risk of GICs due to potential ischemia-reperfusion injury to the gastrointestinal tract. GICs in the postoperative period can lead to increased morbidity and prolong recovery. Prolonged CPB time may serve as a predictive factor for the development of GICs following heart valve replacement. This study will utilize established diagnostic criteria to define GICs, which include clinical symptoms, laboratory tests, and imaging as necessary, based on standards from critical care and gastrointestinal surgery guidelines. By understanding this correlation, the study aims to reduce the incidence and severity of postoperative GICs and improve surgical outcomes.

Eligibility

Inclusion Criteria:

  • Patients undergoing heart valve replacement with CPB
  • Age ≥ 18 years and ≤ 75 years

Exclusion Criteria:

  • Have received major gastrointestinal surgery within 5 years.
  • History of severe infection (e.g., pneumonia, urinary tract infection) requiring hospitalization within 1 month prior to surgery.
  • Inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, or colitis.
  • Acute gastroenteritis.
  • Clostridium difficile or Helicobacter pylori infection.
  • Chronic constipation.
  • Peptic ulcer.
  • Polyps in the stomach or intestines.
  • Gastrointestinal neoplasms.
  • Abdominal hernia.
  • Irritable bowel syndrome.
  • Acute or chronic cholecystitis, hepatitis.
  • Patients who died intraoperatively or within 24 hours postoperatively.
  • Patients with digestive system tumors.
  • Pregnancy or breastfeeding could affect postoperative medication use and study observations.
  • Involvement in other studies that may interfere with the objective results of this study.

Study details
    Valvular Disease

NCT06697405

Hepatopancreatobiliary Surgery Institute of Gansu Province

30 January 2026

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.